Selective APRIL blockade delays systemic lupus erythematosus in mouse

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Huard, Bertrand ^a,b   Tran, Ngoc Lan ^a   Benkhoucha, Mahdia ^a   Manzin Lorenzi, Céline ^a   Santiago Raber, Marie Laure ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPHE; APRIL PROTEIN; AUTOANTIBODY; CHROMATIN AUTOANTIBODY; DNA ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; TNFSF13 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INJURY; MALE; MORTALITY; MOUSE; NONHUMAN; PROTEINURIA; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; BLOOD; C57BL MOUSE; DRUG ANTAGONISM; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NEW ZEALAND BLACK MOUSE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; WESTERN BLOTTING;

MUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BLOTTING, WESTERN; FEMALE; FLOW CYTOMETRY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPLEEN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857073787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031837     Document Type: Article

References (29)

1. Haubitz M, (2010) New and emerging treatment approaches to lupus. Biologics 4: 263-271.
2. Levesque MC, (2009) Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 157: 198-208.
3. Yu G, Boone T, Delaney J, Hawkins N, Kelley M, et al. (2000) APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 1: 252-256.
4. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, et al. (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111.
5. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, et al. (2005) Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 12: 637-648.
6. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, et al. (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201: 1375-1383.
7. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, et al. (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293: 2111-2114.
8. Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, et al. (2004) APRIL-deficient mice have normal immune system development. Mol Cell Biol 24: 997-1006.
9. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, et al. (2004) Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A 101: 3903-3908.
10. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999.
11. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, et al. (2004) Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 173: 3524-3534.
12. Liu W, Szalai A, Zhao L, Liu D, Martin F, et al. (2004) Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 50: 1884-1896.
13. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, et al. (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116: 724-734.
14. Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, et al. (2010) Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 62: 1457-1468.
15. Kawasaki A, Tsuchiya N, Ohashi J, Murakami Y, Fukazawa T, et al. (2007) Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese. Rheumatology (Oxford) 46: 776-782.
16. Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y, (2010) Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol 135: 118-124.
17. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, et al. (2005) Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 64: 1065-1067.
18. George-Chandy A, Trysberg E, Eriksson K, (2008) Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 10: R97.
19. Burjanadze M, Matthes T, McKee T, Passweg J, Huard B, (2009) In situ detection of APRIL-rich niches for plasma-cell survival and their contribution to B-cell lymphoma development. Histol Histopathol 24: 1061-1066.
20. Mohr E, Serre K, Manz RA, Cunningham AF, Khan M, et al. (2009) Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol 182: 2113-2123.
21. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, et al. (2007) Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 109: 331-338.
22. Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, et al. (2011) Production of the plasma-cell survival factor APRIL peaks in myeloid precursor cells from human bone marrow Blood In press.
23. Chu VT, Frohlich A, Steinhauser G, Scheel T, Roch T, et al. (2011) Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 12: 151-159.
24. Tsantikos E, Oracki SA, Quilici C, Anderson GP, Tarlinton DM, et al. (2010) Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. J Immunol 184: 1348-1360.
25. Kikuchi S, Santiago-Raber ML, Amano H, Amano E, Fossati-Jimack L, et al. (2006) Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus. J Immunol 176: 3240-3247.
26. Amano H, Amano E, Santiago-Raber ML, Moll T, Martinez-Soria E, et al. (2005) Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus. Arthritis Rheum 52: 2790-2798.
27. Santiago-Raber ML, Amano H, Amano E, Baudino L, Otani M, et al. (2009) Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum 60: 2408-2417.
28. Yang M, Hase H, Legarda-Addison D, Varughese L, Seed B, et al. (2005) B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol 175: 2814-2824.
29. Izui S, Higaki M, Morrow D, Merino R, (1988) The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW×C57BL/6)F1 male mice, but not in C57BL/6 male mice. Eur J Immunol 18: 911-915.